In affiliation with Hamilton Health Sciences
and the Department of Oncology at McMaster
University
MARKHAM, ON, July 12, 2018 /CNW/ - MedReleaf Corp. (TSX:LEAF)
("MedReleaf" or the "Company"), in collaboration with the Ontario
Clinical Oncology Group ("OCOG") today announced it will sponsor a
cancer trial to improve the management of cancer pain using medical
grade cannabis oil.
The OCOG directed by Dr. Mark
Levine will coordinate the trial. Dr. Marissa Slaven, a specialist in pain management
and palliative care is the Principal Investigator. The study will
be conducted at the HHS Juravinski Cancer Centre in Hamilton over a one-two year period. Patients
with cancer related pain will be administered MedReleaf's uniquely
formatted cannabis oil capsules with the objective of improving
pain management.
Cancer patients experiencing pain despite other pain medications
may be eligible to participate. The aim of the trial is to assess
the effect of cannabis oil in relieving their symptoms and to gain
information on the best oral dosing regimen. Patients will receive
an oil combining THC and CBD.
"Patients with cancer often suffer from significant pain and we
know that while managing the pain with narcotics is often
necessary, it is also fraught with issues," said Dr. Marissa Slaven. "Anecdotally, cancer patients
have been telling us that cannabis products help their pain. Thanks
to MedReleaf's commitment to advancing medical science we will now
be able to start gathering the data needed to help our patients
live better."
"Collaborating with the Ontario Oncology Group under the
direction of Dr. Levine and its affiliates speaks to MedReleaf's
foundation as an R&D driven company," said Neil Closner, CEO MedReleaf. "We are thrilled to
have the opportunity to be involved in this important cancer trial
which has the potential to positively impact the lives of cancer
patients while advancing our understanding of the therapeutic
benefits of medical cannabis and validating new treatment options
for patients."
About OCOG
OCOG is an academic trials group based in the Escarpment Cancer
Research Institute, a joint research institute of Hamilton Health
Sciences and McMaster University. OCOG
works with networks of investigators to design and conduct cancer
clinical trials provincially, nationally, and beyond. OCOG was
established in 1982 and since then over 12,000 patients have been
entered in OCOG studies. The results of which have impacted on
clinical care.
For more information on this and other cancer clinical trials,
please visit www.ocog.ca
About MedReleaf Corp.
Canada's most awarded
licensed producer, MedReleaf is an R&D-driven company
dedicated to innovation, operational excellence and the production
of industry leading, top-quality cannabis. Sourced from around the
world and carefully cultivated in one of two state-of-the-art
ICH-GMP and ISO 9001 certified facilities in Ontario, with a
third facility currently in development, a full range of
premium MedReleaf products are delivered to the global
medical market. We serve the therapeutic needs of patients seeking
safe, consistent and effective medical cannabis and provide a
compelling product offering for the adult-use recreational
market.
For more information on MedReleaf, its products, research
and how the company is helping patients #livefree, please visit
www.medreleaf.com or follow @medreleaf
SOURCE MedReleaf Corp.